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Alzheimer’s disease (AD) is clinically characterized by progressive memory loss,
behavioral and learning dysfunction and cognitive deficits, such as alterations in social
interactions. The major pathological features of AD are the formation of senile plaques
and neurofibrillary tangles together with neuronal and vascular damage. The double
transgenic mouse model of AD (2xTg-AD) with the APPswe/PS1dE9 mutations shows
characteristics that are similar to those observed in AD patients, including social
memory impairment, senile plaque formation and vascular deficits. Mesenchymal stem
cells (MSCs), when transplanted into the brain, produce positive effects by reducing
amyloid-beta (Aβ) deposition in transgenic amyloid precursor protein (APP)/presenilins1
(PS1) mice. Vascular endothelial growth factor (VEGF), exhibits neuroprotective effects
against the excitotoxicity implicated in the AD neurodegeneration. The present study
investigates the effects of MSCs overexpressing VEGF in hippocampal neovascularization,
cognitive dysfunction and senile plaques present in 2xTg-AD transgenic mice. MSC
were transfected with vascular endothelial growth factor cloned in uP vector under
control of modified CMV promoter (uP-VEGF) vector, by electroporation and expanded
at the 14th passage. 2xTg-AD animals at 6, 9 and 12 months old were transplanted
with MSC-VEGF or MSC. The animals were tested for behavioral tasks to access
locomotion, novelty exploration, learning and memory, and their brains were analyzed by
immunohistochemistry (IHC) for vascularization and Aβ plaques. MSC-VEGF treatment
favored the neovascularization and diminished senile plaques in hippocampal specific
layers. Consequently, the treatment was able to provide behavioral benefits and reduce
cognitive deficits by recovering the innate interest to novelty and counteracting memory
deficits present in these AD transgenic animals. Therefore, this study has important
therapeutic implications for the vascular damage in the neurodegeneration promoted
by AD.
Keywords: Alzheimer’s disease, memory deficits, mesenchymal stem cell, vascular endothelial growth factor,
angiogenesis, amyloid plaques
INTRODUCTION
The extensive deposition of amyloid-β (Aβ) peptide, which forms
senile plaques, in the cortex and hippocampus is one of the main
pathological features of Alzheimer’s disease (AD). At present, all
missense mutations that are linked to the familial form of AD
Abbreviations: 2xTg-AD, double transgenic mouse of AD; Aβ, amyloid-beta;
AD, Alzheimer’s Disease; APP, amyloid precursor protein; DMEM, Dulbecco’s
Modified Eagle’s Medium; GFP, green fluorescence protein; GrDG, granular
layer; HIF-1, hypoxia-inducible factor 1; LMol, lacunosum molecular; MoDG,
molecular layer; MSCs, mesenchymal stem cells; OF, open-field; PM-DAT,
plus-maze discriminative avoidance task; PoDG, polymorphic layer; PS1,
presenilins1; SR, social recognition; VEGF, vascular endothelial growth factor.
are present in genes related to the metabolism of Aβ, such as the
amyloid precursor protein (APP) and presenilins1 and 2 (PS1 and
PS2; Bertram and Tanzi, 2004). Evidences indicate that the Aβ
peptide is implicated in the vascular dysfunction present in AD.
Accumulating Aβ peptide in the brain parenchyma of AD patients
is responsible for reduced vascular permeability (Bergamaschini
et al., 2004), leading to the loss of blood flow by capillary bed
degeneration (Zekry et al., 2002). In vitro assays show that at
high concentrations, the Aβ peptide limits the formation of new
capillaries because it promotes the degeneration of endothelial
cells. In in vivo AD studies, Aβ inhibits angiogenesis, suppresses
the formation of blood vessels (Paris et al., 2004), and causes
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vessel disruption, which is induced by Aβ deposition in the vessel
walls (Hardy and Cullen, 2006; Zhang-Nunes et al., 2006). In
transgenic AD models, the animals exhibit several symptoms sim-
ilar to those observed in AD patients, including Aβ accumulation
in the brain parenchyma and around the blood vessels, as well
as significant vascular abnormalities and cognitive and social
behavioral deficits.
Mesenchymal stem cells (MSCs), which are found in the
stroma of various organs, represent the most studied population
of adult stem cells. Because of the ease in obtaining these cells
from the bone marrow or fat tissue, MSCs are excellent candidates
for cell therapies (Brazelton et al., 2000). These cells can be rapidly
mobilized to ischaemic sites (Rafii et al., 2002; Majka et al.,
2003), where they primarily produce microglia and endothelial
cells (Zhang et al., 2002). After being transplanted into the brain,
MSCs produce positive effects by reducing Aβ deposition and
restoring microglial function in transgenic APP/PS1 mice (Lee
et al., 2010; Kim et al., 2012a).
Angiogenic factors, particularly vascular endothelial growth
factor (VEGF), which is induced during hypoxia by transcrip-
tional factor hypoxia-inducible factor 1 (HIF-1; Leung et al.,
1989), are now known to exhibit neuroprotective effects against
the excitotoxicity implicated in the neurodegeneration present
in AD (Greenberg and Jin, 2005). VEGF is the main regulator
of vascular functions and angiogenesis, including increases in
permeability, endothelial cell growth (Ferrara, 1999) and glucose
transportation (Sone et al., 2000; Yeh et al., 2008). Admin-
istration of VEGF-modified MSCs prevents heart dysfunction
after myocardial infarction by promoting myogenesis and angio-
genesis (Gao et al., 2007) and increasing the dopaminergic
differentiation in hemiparkinsonian rats (Xiong et al., 2011). In
addition, combined with Ang-1, MSCs contribute to the func-
tional recovery in cerebral ischaemia (Toyama et al., 2009). In
in vitro experiments, VEGF binds with high affinity to Aβ, co-
localizing and accumulating in conjunction with this peptide in
the senile plaques of the brain parenchyma of AD patients (Yang
et al., 2004). Aβ sequesters the soluble VEGF present around
the senile plaques, reducing its availability for protecting cerebral
vessels and neurons against the hypoperfusion that occurs in AD
pathology (Wang et al., 2011). Thus, an appropriate therapeutic
strategy in AD might be the supply of VEGF by local gene
transfer.
Considering the similarities to clinical AD cases, the trans-
genic APPswe/PS1dE9 mouse model described by Jankowsky
et al. (2004) represents a useful model to investigate cell-based
therapies in AD. These transgenic animals have decreased vas-
cularisation and angiogenesis rates, have accumulation of the Aβ
peptide and cognitive and memory deficits. Based on these obser-
vations, the present study proposed to investigate the functional
recovery of the hippocampal vasculature in a double transgenic
mouse model of AD (2xTg-AD) with the APPswe/PS1dE9 muta-
tions by transplanting bone marrow MSCs overexpressing VEGF
(MSC-VEGF). Our working hypothesis was that the MSCs would
promote neovascularization, which would be potentiated by high
VEGF expression and contribute to the Aβ peptide clearance,
consequently improving the cognitive deficits that are present
in AD.
METHODS
SUBJECTS
2xTg-AD male congenic mice (APPswe/PS1dE9, B6.Cg-Tg
(APPswe,PSEN1dE9)85Dbo/J) obtained from Jackson Laboratory
(JAX® Mice and Services, Bar Harbor, Maine, USA), were bred,
raised and maintained in the Center for the Development of
Experimental Models in Medicine and Biology of the Universi-
dade Federal de São Paulo. The mice were housed in polypropy-
lene home cages (41 × 34 × 16.5 cm) in a pathogen-free facility.
Animals (weighing 30–35 g) were housed under controlled tem-
perature (22–23◦C) and lighting (12 h light, 12 h dark, lights on
at 6:45 a.m.) conditions. Rodent chow and water were available
ad libitum. The animals were maintained in accordance with the
National Institute of Health Guide for the Care and Use of Lab-
oratory Animals (NIH Publication No. 8023), revised 2011. The
Ethics Committee of UNIFESP approved all of the experiments
under the protocol #0396/09.
MESENCHYMAL STEM CELL PREPARATION AND TRANSFECTION
Bone marrow MSCs from 6-week-old C57BL/6-Tg(ACTB-
EGFP)10sb/J transgenic mice (JAX® Mice and Services, Bar Har-
bor, Maine, USA) were collected from femurs and tibias by
flushing with culture medium (DMEM, Dulbecco’s Modified
Eagle’s Medium, Gibco, San Diego, CA, USA). The cells were
centrifuged and resuspended in DMEM low glucose containing
inactivated 10% foetal bovine serum Gibco), 3.7 g/l HEPES (N-
2-hydroxyethylpiperazine-N′-2-ethane-sulphonic acid, Sigma-
Aldrich), 1% 200 mM L-glutamine 100x (Gibco) and 1% PSA
(Gibco). The cell number and viability were determined by trypan
blue staining (Gibco) and reached a final cell density of 5 ×
106 cells/ml. The cells were incubated at 37◦C for 72 h, and the
adherent cells, which were considered MSCs, were maintained in
culture until reaching ∼80% semi-confluence. Then, the MSCs
were washed, incubated with trypsin-ethylenediaminetetraacetic
acid (EDTA) (StemCell Technologies, Vancouver, Canada) and
prepared to be frozen with a cryoprotectant solution of dimethyl-
sulphoxide (DMSO, MP Biomedicals, Santa Ana, USA) and Fetal
Bovine Serum (FBS).
For transfection, the cells were unfrozen and expanded until
the 10th passage, when the transfection was performed. Human
VEGF 165 cDNA from uP-VEGF (Sacramento et al., 2010) was
obtained after digesting with Hind III and Xba I and inserted
into the pVAX (Invitrogen) at the same sites. An insert contain-
ing the CMV promoter, VEGF and polyA sequences from this
vector was excised using NruI and Pvu II and inserted into the
pT2BH vector (kindly provided by Dr. Perry Hackett, University
of Minnesota), which was previously treated with Eco RV. The
final product was named pT2-VEGF. For transfection, 5 × 105
cells were resuspended in 50 µL of SMEM, mixed with pT2-VEGF
(4 µg) and pCMV-SB100X (4 µg), which expressed the sleeping
beauty transposase (Mátés et al., 2009) and were electroporated
applying 1,500 V/cm and 12 pulses with a 150 ms duration (BTX
electroporator, MA, USA). After electroporation, the cells were
seeded in 6-well plates and expanded until the 14th passage. Even
though less cell passages are preferable for cell therapy, in practice
more passages are required to obtain enough number of cells for
transplantation. Here, we transfected MSC by electroporation,
Frontiers in Aging Neuroscience www.frontiersin.org March 2014 | Volume 6 | Article 30 | 2
Garcia et al. MSC-VEGF induced neovascularization in the hippocampus of 2xTg-AD mice
which is a very efficient method, but also increase cell unviability.
Consequently, more cell passages are required to eliminate unvi-
able cells and obtain enough number of transfected viable cells
(Martin et al., 2014, in press). With appropriate MSC controls
to qualify the cells, MSC cell differentiation to osteoblast and
adipocyte are the best method to characterize MSC cells validating
14 passages are well for in vivo experimentation. VEGF expression
was evaluated by ELISA (BD Biotech, Franklin Lakes, USA).
CELL TRANSPLANTATION
2xTg-AD animals at 6, 9 and 12 months of age (n = 10 per
group) were anesthetized, and 1 × 106 of the cells in a 5 µL
volume were stereotaxically injected in the lateral ventricle with
MSCs or MSC-VEGF. The cell suspension was placed in a Nar-
ishige microinjector (Narishige Scientific Instrument Laboratory,
Tokyo, Japan) guided with the stereotaxic apparatus. The follow-
ing coordinates from the atlas by Paxinos and Franklin (2004)
were used: −0.34 mm posterior to bregma, −0.9 mm lateral to
the midline and 2.3 mm ventral to the skull surface. The age-
matched wild type-saline (WT-SAL) and 2xTg-AD groups (n =
10 per group) were injected with saline at the same coordinates
and volume (Alzheimer’s disease-saline (AD-SAL)).
OPEN-FIELD EVALUATION (OF)
Forty days after transplantation, mice were tested in the open-
field (OF) task to evaluate general locomotor activity. The OF
apparatus consisted of a circular wooden arena 40 cm in diameter,
bounded by 50 cm high wall, with an open top and the floor
divided into 19 segments by black painted lines on the wooden
floor. The mice were exposed to the OF arena to quantify their
basal general activity for 5 min. Faecal pellets were removed, and
the apparatus was cleaned with 5% ethanol after every subject.
During the session, the observer was unaware of the experimental
design. The parameters assessed for the present studies were the
total locomotion frequency of the squares/segments traversed.
All of the behavioral tests were conducted under standard room
lighting.
SOCIAL RECOGNITION TEST (SR)
The mice were tested in the social recognition test (SR) as
described elsewhere (Choleris et al., 2003; Prado et al., 2006)
to assess their social recognition memory and novelty reaction.
Seven days before the SR test, the animals were kept in individual
cages to establish territorial dominance. Six-week-old Swiss male
mice were used as intruders. Before the first trial, an empty
chamber was placed in the test cage with the subject mouse
to allow spontaneous exploration (Figure 1). During an “initial
encounter”, an intruder was placed inside a transparent acrylic
chamber with several orifices on the walls. The sessions consisted
of five trials of 5 min each, separated by 10 min intervals. In the
subsequent four trials, the subject mouse was exposed to the same
intruder. In the last trial (5th), a new intruder (2nd intruder) was
placed in the same acrylic chamber (which was properly cleaned
to remove the odor of the previous intruder), and the time spent
sniffing was quantified again (Figure 1). The time spent sniffing
in the social interactions was scored with a stopwatch by an
observer blinded to the phenotype or treatment. The duration of
investigation by the host mouse, consisting of sniffing the intruder
through the orifices, was summed over the course of the trial and
was used as a measure of social recognition. A reduction in the
FIGURE 1 | Social recognition test. Each session consisted of five trials of
5 min each separated by 10 min intervals. In subsequent trials, the subject
mouse was exposed to the same intruder. In the last trial, a new intruder
(second intruder) was placed in the same acrylic chamber (which was
properly cleaned to remove the odors of the previous intruder), and the
sniffing time was quantified again.
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time spent sniffing between the 1st and 4th trials indicated social
recognition. An increase in the time spent sniffing in the 5th trial
compared to the 4th trial indicated reaction to the novelty (Prado
et al., 2006).
PLUS-MAZE DISCRIMINATIVE AVOIDANCE TASK (PM-DAT)
As described elsewhere (Fernandes et al., 2013), the apparatus
employed in the plus-maze discriminative avoidance task (PM-
DAT) is a modified elevated plus-maze made of wood. The
apparatus has two enclosed arms with sidewalls and no top
(28.5 × 7 × 18.5 cm). The enclosed arms are opposite to two
open arms (28.5 × 7 cm). A non-illuminated, 100 W lamp and
a hair dryer were placed over the center of one of the enclosed
arms (aversive enclosed arm). In the training session, each mouse
was placed at the center of the apparatus, and during a 10 min
period, the aversive stimuli were administered every time the
animal entered the enclosed arm containing the lamp and the
hair dryer and was continued until the animal left the arm. The
aversive stimuli consisted of both the illumination of the 100 W
light and cold air blow produced by the hair dryer. In the test
session, which was performed in the same room 24 h after the
training, mice were again placed in the center of the apparatus
and were observed for 3 min; however, the mice did not receive the
aversive stimuli when they entered the aversive enclosed arm even
though the non-illuminated lamp and the hair dryer were still
placed on the middle of this arm to help distinguish between the
aversive and non-aversive arms. In all experiments, the animals
were observed in a blind manner, and the apparatus was cleaned
with a 5% alcohol solution after each behavioral session. The
percentage of time spent in the aversive enclosed arm (time spent
in aversive enclosed arm/time spent in both enclosed arms ×
100) was calculated. Learning and memory were evaluated by
the percentage of time spent in the aversive enclosed arm during
training and testing, respectively. All the measures taken during
the PM-DAT were obtained manually.
IMMUNOHISTOCHEMISTRY
At the end of the behavioral tests, the animals were deeply
anesthetized and perfused through the heart with 50 mL of
phosphate-buffered saline (PBS) followed by 200 mL of 4%
paraformaldehyde at 4◦C. Coronal brain cryostat sections (40 µm
thick) were made between bregma−1.34 and bregma−2.80 mm,
according to the stereotaxic coordinates of the mouse brain atlas
(Paxinos and Franklin, 2004). Sections of the dorsal hippocampus
were selected (16 per animal) to quantify the senile plaques, blood
vessels and astrocytic and microglial cells by immunohistochem-
istry using human Aβ (6E10 antibody), CD31, Glial Fibrillary
Acidic Protein (GFAP) and Iba-1 markers, respectively. Free-
floating sections were washed in PBS and incubated separately
overnight with the following primary antibodies, which were all
diluted in PBS (except CD31, which required permeabilization
with Triton-X): mouse anti-Aβ6E10 (1:300, Covance, San Diego,
USA), mouse anti-CD31 (1:50, Pharmingen, San Jose, USA),
mouse anti-GFAP (1:300, Dako, Glostrup Denmark) and mouse
anti-Iba1 (1:300, Wako Chemicals, Richmond, USA). After incu-
bation, the sections were washed in PBS and incubated in the
ABC kit solutions (Vectashield, Vector, Burlingame, CA, EUA) for
1.5 h. The sections were stained with diaminobenzidine (DAB,
Sigma-Aldrich Corporation, St. Louis, EUA) and mounted on
slides and sealed with coverslips.
For the immunofluorescence, after being incubated with the
primary antibody, the sections were incubated with a secondary
antibody conjugated to the Alexa Fluor 546 fluorophore (1:600,
Molecular Probes, Life Technologies, Grand Island, USA) for 1
h. For double-labeling, the sections were also incubated with
anti-GFP antibody conjugated to Alexa Fluor 488 (1:600, Molec-
ular Probes) for 1 h. The sections were mounted on slides
and sealed with coverslips using the mounting medium with
4′,6-Diamidino-2-Phenylindole (DAPI) (Vectashield) to stain the
nuclei.
IMMUNOHISTOCHEMICAL ANALYSIS
All of the slides were examined using a light microscope (Nikon
80i), and the images were captured and digitized using the
Nikon ACT-1 v.2 system and analyzed with the Image J soft-
ware. The quantification of the immunohistochemical analysis
for Aβ plaques, astrocytes and microglial cells was performed by
counting with the Image J software. Four dorsal hippocampal
slices per animal (4 slices for each marker, n = 5/per group) and
an average of eight non-overlapping fields per slice, totalling 32
fields per hippocampus for each animal were analysed at 40x
magnification. In each section, nuclear profiles of GFAP and Iba1
cells and Aβ plaques nuclei were counted by an observer blind to
the experimental condition. The Paxinos atlas was used to identify
and delineate the analyzed regions (Paxinos and Franklin, 2004).
For the quantification of microvessels, the longitudinal vessel
segment between the two nodes (join points) was considered
as a vessel unit. Vessels were counted in eight acquired non-
overlapping images per slice section of each animal at 40x mag-
nification, and four hippocampal slices per animal were analyzed.
The total number of vessels per hippocampal slice was considered
to calculate the mean for each animal and for the group. All
quantifications were performed by an observer blinded to the
experimental condition of each animal.
To assess the localization and differentiation of the green
fluorescence protein (GFP)-positive MSCs, immunofluorescence
assays using double-labeling with GFP and the appropriate above
mentioned antibodies were performed. All of the images were
captured and digitized using the Nikon ACT-1 v.2 system flu-
orescence images) or the Spinning Disc System Leica TCS SP5
(confocal images).
STATISTICAL ANALYSIS
The data were analyzed using a one- or two-way and repeated
analysis of variance (ANOVA) followed by the Duncan, Tukey or
Bonferroni tests when necessary. A probability of P < 0.05 was
considered significant in all comparisons.
RESULTS
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) PRODUCTION BY
MESENCHYMAL STEM CELL (MSC)-VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) CELLS
The MSC-VEGF cells produced more than 2,000 pg/ml/1 × 106
cells in the medium 4 days after transfection, but the production
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decayed to 424 ± 46 pg/ml/1 × 106 cells on 10th day and this
level had been maintained thereafter. Therefore, this is a reliable
demonstration of stable genetic modification and of correct func-
tioning of gene expression.
MESENCHYMAL STEM CELL (MSC)-VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) TRANSPLANTATION IN THE DOUBLE TRANSGENIC
MOUSE MODEL OF ALZHEIMER’S DISEASE (2xTg-AD) MICE AT 6 AND 9
MONTHS OF AGE WAS ABLE TO RECOVER SOCIAL RECOGNITION
MEMORY AND THE INNATE INTEREST IN NOVELTY
The ANOVA with repeated measurements for sniffing durations
with treatment as a between-subject and time as a within-
subject revealed that 6-month-old mice, both the control
(WT-SAL) and AD animals (AD-SAL, AD-MSC, AD-MSC-
VEGF), recognized the same intruder (e.g., loss of interest
shown by decreased sniffing time over the four trials—a reduc-
tion in the frequency of exploratory behavior) and showed
elevated sniffing times when the intruder mouse was changed
in the 5th trial; this behavior was indicative of intense
exploratory behavior and innate interest (repeated measures
ANOVA followed by the Bonferroni multiple comparisons test;
P < 0.0001) (Figure 2A). The WT-SAL mice and AD-MSC-
VEGF-transplanted mice showed similar exploration times and
interest levels in all five trials, and both groups differed
from the AD-SAL and AD-MSC mice in all trials (P <
0.001).
At 9 months, the sniffing duration of the WT-SAL, AD-
MSC and AD-MSC-VEGF animals decreased throughout the
four initial trials, which was indicative of intruder recognition
(repeated measures ANOVA followed by the Bonferroni multiple
comparisons test; P < 0.0001) (Figure 2B). The AD-MSC-VEGF
mice showed the same pattern of exploration time as the WT-SAL
mice, and both groups maintained interest in exploring the new
intruder, although the exploration time of the AD-MSC-VEGF
mice was shorter compared with that of the WT-SAL mice (P <
0.0001).
At 12-months-old, the WT-SAL, AD-MSC and AD-MSC-
VEGF mice presented a descending sniffing curve of exploration
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FIGURE 2 | Social recognition memory and locomotor activity
evaluation. The social recognition test (SR) in the wild type (WT-SAL) and
2xTg-AD animals (AD-SAL; AD-MSC and AD-MSC-VEGF), as evaluated by
the sniffing duration (seconds) to the same intruder (session 1–4) and to a
different intruder (5th session) at 6 months (A), 9 months (B) and 12
months of age (C). Repeated measures ANOVA followed by post hoc
Bonferroni’s test (mean ± standard error, * P < 0.05; ** P < 0.01; ***
P < 0.001, n = 10 per group). Differences between the first four trials are
indicated in the trial number 1, and differences between the 4th and 5th
trials are indicated in trial number 5. Color lines and point markers connect
the mean values for the groups in each session (SAL-WT in blue;
AD-MSC-VEGF in green; AD-MSC in yellow; AD-SAL in red). In (D), the
general locomotor activity of the WT and AD mice groups in the OF test
for each age (6, 9 and 12 months), as evaluated by the total locomotion
frequency of the quadrants traversed. There were no statistical differences
between groups.
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of the same intruder along the four trials (repeated mea-
sures ANOVA followed by the Bonferroni multiple compar-
isons test; P < 0.0001). AD-SAL mice did not show differences
between trials at 12 (and at 9) months indicating reduction
of exploration. WT-SAL also showed reduction in exploration
time when comparing from 6 to 12 months, as shown by a
less accentuated curve at 12 months. However, the curve for
the WT-SAL mice was greater than that of the AD treated mice
(P < 0.0001). Moreover, the AD animals (treated or untreated)
lost interest in exploring the new intruder (from 4th to 5th
trial), which was maintained in the WT-SAL group (P < 0.001)
(Figure 2C).
The WT-SAL mice and all of the AD mice showed similar rates
of total locomotor activity in the open-field test (Figure 2D).
There were no significant variations comparing between geno-
types, ages or age-treatment groups.
MESENCHYMAL STEM CELL (MSC) AND MESENCHYMAL STEM CELL
(MSC)-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
TRANSPLANTATION DISTINCTLY MODULATED MEMORY ACQUISITION
AND RETENTION IN THE DOUBLE TRANSGENIC MOUSE MODEL OF
ALZHEIMER’S DISEASE (2xTg-AD) MICE
In the training session, repeated measures ANOVA examining
the percent time spent in the aversive enclosed arm parameter
with treatment as a between-subject factor and time (minutes
of observation) as a repeated measures factor was performed.
This analysis revealed significant effects of time (P < 0.001),
treatment (MSC × MSC-VEGF) (P < 0.001), as well as time ×
treatment interaction significant effects (P < 0.01) (Figure 3A).
One-way ANOVA for percent time spent in the aversive arm
in the session as whole showed significant effects of treatment
(P < 0.001). In fact, the 12-month-old WT mice displayed an
increased percent time in the aversive enclosed arm compared
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FIGURE 3 | Plus-maze discriminative avoidance task (PM-DAT)
evaluation. The PM-DAT performance of the wild type (WT-SAL) and
2xTg-AD animals (AD-SAL; AD-MSC and AD-MSC-VEGF) during the training
(A and B) and testing (C) for the three ages. ANOVA followed by post hoc
Duncan’s test (mean ± standard error, * P < 0.05; ** P < 0.01; *** P <
0.001, n = 10 per group). In A, color lines and point markers connect the
mean values for the groups in minute of observation during the training
(WT-SAL in blue; AD-MSC-VEGF in green; AD-MSC in yellow; AD-SAL in red).
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to WT mice at 6 or 9 months age. Moreover, the effect of
age seemed to be more pronounced in 2xTg-AD because mice
spent a progressively higher exploration of this arm as the age
advanced (AD-12 m > AD-9 m > AD-6 m). In 9- or 12-
month-old 2xTg-AD mice, the MSC improved the acquisition
deficits of the task while the MSC-VEGF treatment recovered it
to control levels. No effects were observed in 6-month-old mice
(Figure 3B).
In the test session, performed 24 h after training, the ANOVA
followed by Duncan’s test showed that mice at 12 months, irre-
spectively of genotype, spent a significant longer percent time in
the aversive enclosed arm compared to their control WT groups.
In addition, the treatments with MSC alone or MSC-VEFG abol-
ished the memory impairment displayed by the 2xTg-AD mice
at 6 months of age (P < 0.001). In 9- or 12-month-old 2xTg-
AD mice, only the MSC-VEGF cells transplantation abolished the
amnesia presented by these animals (Figure 3C).
MESENCHYMAL STEM CELL (MSC)-VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) TRANSPLANTATION PROMOTED
NEOVASCULARIZATION IN THE HIPPOCAMPUS OF THE DOUBLE
TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE (2xTg-AD)
MICE
The vascularisation in the 2xTg-AD mice was evaluated at the 3
selected ages (6, 9 and 12 month-old) in the whole hippocampus
by the expression of CD31 (PECAM-1) in the blood vessels.
The two-way ANOVA for this quantification revealed a sig-
nificant effect for the age × treatment interaction (P = 0.0299).
Tukey’s test showed a gradual decrease in the microvessel number
from 6 to 12 months in the mice from all of the groups (P <
0.0001), and this difference was more robust in the AD-SAL mice
at the three analyzed ages (P < 0.0001).
At the three ages, the VEGF treatment induced neovascular-
ization compared with the AD-SAL group (P < 0.01) but did not
result in the total recovery of the vascular density as these groups
still differed from the WT-SAL group (P < 0.01). The AD-MSC
treatment promoted the same effect at only 6 months of age (P <
0.01) (Figure 4).
MESENCHYMAL STEM CELL (MSC)-VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) TREATMENTS REDUCED THE NUMBER OF
AMYLOID-BETA (Aβ) PLAQUES IN THE DENTATE GYRUS COMPARED TO
AD-SAL
To identify and quantify senile plaques (Aβ plaques) in the
hippocampus, immunohistochemistry was performed using the
Aβ6E10 antibody, which reacted with the 1–16 residue amino
acids of the human Aβ protein (Figure 5). To evaluate the
effect of the treatments in diminishing the number and the
distribution of the Aβ plaques of the 2xTg-AD in the hip-
pocampus, we quantified the senile plaques in the hippocam-
pal stratum oriens, pyramidal, radiatum, lacunosum molecular
(LMol), molecular (MoDG), granular (GrDG) and polymorphic
(PoDG) layers. Because we did not detect Aβ plaques in the
WT animals at any of the ages tested here, we did not include
WT-SAL animals in this analysis. We compared only the AD
animals of the three groups: AD-SAL, AD-MSC and AD-MSC-
VEG.
The two-way ANOVA revealed an interaction effect between
age × treatment, indicating that the number of Aβ plaques
increased with age and was more intense in the AD-SAL ani-
mals in the stratum oriens (P = 0.0090), MoDG (P = 0.0182)
and PoDG (P = 0.0133), whereas in the LMol and GrDG, the
differences were evident only when the ages were compared
(LMol, P < 0.0001; GrDG, P < 0.0001). Tukey’s test detected
differences among the AD-SAL, AD-MSC and AD-MSC-VEGF
mice in the stratum oriens, LMol, MoDG, GrDG and PoDG
layers at 12-months-old but not at 6- and 9-months-old (P <
0.01) (Figures 5A–E). In the LMol, GrDG and PoDG layers, the
VEGF treatment significantly decreased the number of Aβ plaques
compared to the AD-SAL animals at 12 months of age (P <
0.01). In the stratum oriens and MoDG, this effect was detected
for both treatments (MSC and MSC-VEGF) (P < 0.01). When
considering the whole hippocampus, significant differences could
still be detected in older animals (12 month-old), which indicate
a decreased number of Aβ plaques in the AD-MSC-VEGF mice
compared with the AD-SAL mice (P < 0.01) (Figure 5F). No
significant difference was found for the distribution of Aβ plaques
in the pyramidal and radiatum layers at any of the three ages (6,
9 or 12 month-old) among the AD-SAL, MSC and MSC-VEGF
treatments.
MESENCHYMAL STEM CELL (MSC) AND MESENCHYMAL STEM CELL
(MSC)-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
TREATMENTS REDUCED THE EXPRESSION OF ASTROCYTES AND
MICROGLIAL CELLS IN THE HIPPOCAMPUS
The quantification of the astrocyte and microglia population in
the hippocampus was performed by counting respectively GFAP,
an intermediate filament protein expressed in astrocytic cells, and
Iba1+ cells, specifically expressed in macrophages/microglia.
At 6 months, no difference was detected in the GFAP+ cell
numbers among the different experimental groups. However, the
number of GFAP+ cells in the hippocampus of the AD-SAL
mice significantly increased at 9 and 12 months compared with 6
months (two-way ANOVA, followed by Tukey’s test; P < 0.0001).
At the ages of 9 and 12 months, the AD-SAL mice showed a higher
number of GFAP cells compared with the WT-SAL mice (P <
0.01), and at 9 months, the MSC-VEGF treatment reduced the
number of astrocytes compared with the AD-SAL treatment (P <
0.01), but this reduction did not reach the level observed in the
WT-SAL mice (Figure 6).
The two-way ANOVA for the Iba-1+ cell quantification in the
hippocampus revealed the interaction effects of age × treatment
(P = 0.0328). The number of Iba-1+ cells increased with age
(P < 0.0001), and the comparisons of the treatments revealed
significant differences (P < 0.0001), except for WT-SAL vs. AD-
MSC-VEGF and AD-SAL vs. AD-MSC. At 6 months, no differ-
ences were observed among the groups. At 9 and 12 months,
significant differences were detected, revealing an increase in the
Iba-1+ cells in the AD-SAL and AD-MSC groups compared with
the age-matched WT-SAL groups (P < 0.01). At 12 months, a
difference was also detected between the AD-SAL and AD-MSC-
VEGF groups, indicating a decrease in the Iba-1 cells in the VEGF-
treated mice (P < 0.001) (Figure 7).
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FIGURE 4 | Immunofluorescence and quantification of hippocampal
vascularization. Images above of photomicrographs of CD31 stain for
vascularization in the hippocampus of AD-MSC-VEGF mouse at 9 months
(scale bar 100 µm). Bellow, quantification of microvessels stained by CD31 in
the hippocampus at the ages of 6, 9 and 12 months in the WT-SAL, AD-SAL,
AD-MSC and AD-MSC-VEGF animals (two-way ANOVA followed by Tukey’s
multiple comparisons test, mean ± standard error; * P < 0.05; ** P < 0.01;
*** P < 0.001, n = 5 per group).
The qualitative analysis of GFAP and Iba-1 in 2xTg-AD
animals revealed clusters of activated astrocyte and microglial
cells scattered throughout the hippocampus especially near Aβ
depositions (plaques). Because a function of microglial cells is
clearing the Aβ protein, the location of microglia relative to
the senile plaques was analyzed with immunofluorescence for
double-staining of Iba-1 and Aβ6E10. The immunofluorescence
analysis by confocal microscopy revealed the existence of the co-
localization of clusters of Iba-1 and the Aβ plaques at the three
evaluated ages (Figure 7), as well as the co-localization of GPF
(MSC-VEGF) with GFAP, CD31 and Aβ6E10 markers expressed
by a small amount of transplanted cells around the Aβ plaques in
the cortex (Figure 8).
DISCUSSION
Our results indicated that the MSC-VEGF transplantation
induced significant neovascularization in the hippocampus of
2xTg-AD animals, recovered the innate interest in novelty and
counteracted the social and discriminative type-memories and
learning deficits present in these AD transgenic animals. Addi-
tionally, the transplantation of MSCs alone or MSCs expressing
VEGF reduced Aβ plaques compared to AD-SAL animals. In
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FIGURE 5 | Immunofluorescence and quantification of senile amyloid
(Aβ) plaques in the hippocampal areas. Photomicrographs of 6E10 stain for
Aβ plaques in the hippocampus of 12 months mice of the three AD groups:
AD-SAL, AD-MSC and AD-MCS-VEGF. Note the high concentration and large
Aβ plaques in AD-SAL mouse (scale bar 50 µm). Aβ plaques stained by 6E10
were quantified in the hippocampal areas of (A) stratum oriens, (B)
lacunosum molecular (LMol), (C) molecular (MoDG), (D) granular (GrDG) and
(E) polymorphic (PoDG) layers and (F) in the whole hippocampus of the
AD-SAL, AD-MSC and AD-MSC-VEGF transgenic animals at 6, 9 and 12
months (two-way ANOVA followed by Tukey’s multiple comparisons test,
mean ± standard error; * P < 0.05; ** P < 0.01; *** P < 0.001, n = 7 per
group).
particular, the double transgenic APPswe/PS1dE9 (2xTg-AD) has
been shown to accelerate the processes of Aβ deposition and
cognitive deficits (Jankowsky et al., 2004; Garcia-Alloza et al.,
2006). Using different animal models of AD, recent studies have
documented the beneficial effects of MSCs from different sources
to treat the basic memory deficit and formation of amyloid
plaques (Lee et al., 2010; Babaei et al., 2012; Kim et al., 2012a,b).
The social recognition paradigm is a model of social memory
dependent on hippocampal function (Kogan et al., 2000) that
can be used in pathophysiological processes, such as ischemia
and aging, which are known to interfere with these processes
(Terranova et al., 1994; Prediger and Takahashi, 2005) or yet,
in social memory deficits caused by a reduction in cholinergic
tone (Choleris et al., 2003), also present in AD mouse models
(Bories et al., 2012). In our hands, using this resident-intruder
paradigm, the transplantation of MSCs transfected with VEGF
vector was able to improve the social recognition memory and
recover the novelty component of short-term memory impaired
in 2xTg-AD animals. However, in older animals, this condition
was worsened by the accentuated neurodegeneration caused by
the Alzheimer’s genotype, and the robust effect of the VEGF
in improving the social memory deficit in younger animals was
attenuated in older animals and could not reverse the impairment
of the social recognition memory at that age. Interestingly, in
2xTg-AD mice, the exploration time in each session was reduced
as the age increased indicating a typical aging apathy in this AD
model.
In the PM-DAT, the avoidance of the aversive enclosed arm
upon testing has been validated as a measurement of retention,
because amnestic manipulation decreases this effect (Patti et al.,
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FIGURE 6 | Immunofluorescence and quantification of hippocampal
astrocytic cells in the hippocampus. Photomicrographs of GFAP
stain for astrocytes in the hippocampus of AD-SAL mouse at 9
months (scale bar 100 µm). Number of GFAP+ cells counted in the
WT, AD-SAL, AD-MSC and AD-MSC-VEGF mice at 6, 9 and 12
months (two-way ANOVA followed by Tukey’s multiple comparisons
test, mean ± standard error; * P < 0.05; ** P < 0.01; *** P <
0.001, n = 5 per group).
2010). Using this animal model, we demonstrated that in the
training session 2xTg-AD decreased learning levels at 9 and 12
months, as demonstrated by the increased time spent in the
aversive enclosed arm. At these ages, MSC attenuated and MSC-
VEGF abolished this learning deficit reaching the basal levels at
the respective age-matched mice. In testing session, 2xTg-AD
mice showed impaired retrieval of the memory task at the three
evaluated ages in a gradually aging-dependent manner: 12 month
mice showed higher magnitude deficit than 6 and 9 months.
MSC-VEGF treatment was able to recover memory from deficits
present in 2xTg-AD at the three ages (6, 9 and 12 months), while
MSC treatment reduced memory deficits only at 6 months.
Concerning the histological findings, the 2xTg-AD animals
exhibited a significant reduction in vascular density, which wors-
ened with age. The transplantation of MSC-VEGF promoted
an important neovascularization in the 2xTg-AD animals, even
in older animals. This neovascularization may be primarily
attributed to a paracrine signaling effect of the MSC-VEGF, as
only an inexpressive number of transplanted cells was detected in
the hippocampus and in the cortex. These data are in accordance
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FIGURE 7 | Immunofluorescence and quantification of microglial cells in
the hippocampus. Image of double-stained senile plaques (6E10 staining in
green) and Iba-1+ cells (in red) in the hippocampus of AD-SAL animals at 12
months. Note the co-localization of Iba-1 and 6E10 in the merged image
(scale bar 200 µm). The number of Iba-1+ cells counted in the WT, AD-SAL,
AD-MSC and MSC-VEGF mice at 6, 9 and 12 months (two-way ANOVA
followed by Tukey’s multiple comparisons test, mean ± standard error; * P <
0.05; ** P < 0.01; *** P < 0.001, n = 5 per group).
with other authors that could not detect MSCs after 3 weeks post-
injection (Khoo et al., 2011), or did not describe the presence or
differentiation of the cells after transplantation into the brain (Lee
et al., 2010; Babaei et al., 2012). We must consider that MSCs
alone also secreted VEGF, although this secretion did not clearly
increase the number of microvessels. However, the overexpression
of VEGF by MSCs robustly affected the vascular density, which
was consistent with a crucial role of VEGF in vascular function
and consequently in cognitive capacity.
The results of the two memory tests indicated therapeutic
effects of VEGF at the three evaluated ages. The data are consistent
with that observed for neovascularization in animals treated with
VEGF when compared to saline-treated 2xTg-AD. The treatment
did not result in a total recovery of the vascular density as
observed when compared with WT animals. These data are also
consistent with a proportional decrease in memory tests observed
here, suggesting a therapeutic benefits of VEGF by neovascular-
ization.
Cerebrovascular diseases and aging in the cerebral arteries
have been proposed to be connected to the pathogenesis of AD
(Nicoll et al., 2004; Bories et al., 2012). These biological processes
are intimately related to angiogenesis, and VEGF is the main
regulator of them. In the brains of AD patients the soluble VEGF
concentration is decreased because Aβ binds to VEGF forming
aggregate that leads to the loss of angiogenic and neuroprotective
activities (Yang et al., 2004). Therefore, provide on-site of VEGF
should have high therapeutic effect, as we showed here using mes-
enchymal cells overexpressing VEGF that recovered the memory
deficit and had high neovascularization in the hippocampus of
the 2xTg-AD animals. These findings corroborate the results of
Wang et al. (2011), who found that the intraperitoneal injection
of VEGF enhanced hippocampal angiogenesis and decreased Aβ
deposition in the brain, improving cognitive function (Wang
et al., 2011).
A different approach has been proposed in a study using
voluntary physical exercise in 3xTgAD model (García-Mesa
et al., 2011). In this study, physical exercise improved motor
performance and learning capabilities of 3xTg-AD Alzheimer-
like transgenic mice. Moreover, exercise also reduced oxidative
stress and showed beneficial effects on hippocampal physiology.
However, although physical exercise induced positive effects on
synapse strength, redox homeostasis, and general brain func-
tion, it was not able to reduce the hippocampal levels of Aβ
deposition.
Fibrillar deposits of Aβ accumulated in the brains of 2xTg-AD
mice as they aged. Among the animals transplanted with MSC-
VEGF, a reduction in the number of Aβ plaques was evident
in the hippocampus, particularly in the dentate gyrus layers,
which are areas of high incidence of plaques in the 2xTg-AD
mice. These results raised the question of whether the cogni-
tive improvements were caused by reduced Aβ plaques or the
increase in the hippocampal vasculature. The 2xTg-AD mice
showed memory deficit and a possible explanation would be the
increase of Aβ deposition. In fact, the intervention with MSC
improved social and discriminative performance and decreased
Aβ deposition in the hippocampus. However, not in all groups
this effect was evident, and could not be explained by the pres-
ence of the cells in the brain. As suggested by other authors,
the number of MSCs decreased over time when transplanted
into the brain (Khoo et al., 2011), as well as into other tis-
sues (Iso et al., 2007). Thus, another possibility was the ability
of MSCs to secrete factors together with the effect of VEGF
on vascularization. The animals treated with MSCs overex-
pressing VEGF showed better cognitive function compared to
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FIGURE 8 | Images from confocal microscopy reveled GFP+ Mesenchymal
stem cells (MSC)- Vascular endothelial growth factor (VEGF) cells in the
cortex (A–C) and hippocampus (D–I). Double labeling of GFP and GFAP
(A–C), CD31 (D–F) and Aβ6E10 (G–I) markers were detected in mice at 6
(A–C), 9 (D–F) and 12 months old mice (G–I) as indicated by thin arrows (thick
for GFP+ cells only) in merge images (C, F and I). Scale bar = 50 µm.
those treated only with MSCs, suggesting that neovascularization
should be more relevant to the cognitive improvement in these
animals, and the reduction of Aβ plaques in the hippocam-
pus being a consequence of this neovascularization. Thus, it
is imaginable that an increase in the brain vasculature could
avoid the Aβ deposition, consequently improving the cognitive
functions.
As has been shown in a previous study, the amount of Aβ
deposition were not associated to learning and memory impair-
ments observed in 18-month-old mice (Gruart et al., 2008). Wild-
type mice that did not show Aβ deposition also presented motor,
emotional, and learning deficits at this age. Accordingly, our study
described a gradual impairment in social recognition memory
in WT mice over the aging processes (from 6 to 12 months),
WT animals also showed reduction in exploration time when
comparing from 6 to 12 months. However, the curve for the
WT mice was greater than that observed for AD mice. Indeed,
WT animals at 12 months old showed deficit in social memory
when compared to 9 and 6 months old WT mice. Moreover, even
WT animals lost memory acquisition and retention learning in
older ages. The 12-month-old WT mice displayed memory deficit
compared to WT mice at 6 or 9 months age. Even so, the effect
of age seemed to be more pronounced in AD mice. WT mice still
show important differences compared to 2xTg-AD mice.
The increase in the Aβ peptides in the brain and their sub-
sequent deposition into plaques led to an activation of the sur-
rounding microglia and astrocytes (Cagnin et al., 2001). In fact, as
an effect of genotype and aging, the AD mice showed an increased
in astrocytic activity, which was reduced in the VEGF treated
group at 9 months. In older transgenic animals (12 months),
the MSC or MSC-VEGF treatments were able to keep the astro-
cytic activation levels similar to those found in the age-matched
wild type animals, but did not reduce the number of astrocytes
compared to the transgenic AD non-treated levels. It has been
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suggested that reactive astrocytes are present in large numbers
in areas most affected by the disease. The GFAP-positive reac-
tive astrocyte responses were associated with the increase of Aβ
plaque deposits (Wilhelmsson et al., 2006; Kamphuis et al., 2012).
Regarding the reduction of the total number of astrocytes that
occurs in animals treated with MSC and MSC-VEGF, it is likely
caused by the decrease in reactive astrocytes that might occur as a
reduction of inflammation and number of plaques mainly due to
the VEGF treatment. Older AD animals displayed large amounts
of Aβ in the hippocampus, which could suggest that the astrocytic
stimulation would be a mechanism of neuroprotection against Aβ
and other insults.
One important role of microglia in AD that has been recently
accepted is the clearance of the Aβ protein by phagocytosis
(Simard et al., 2006; Lee et al., 2009, 2010). These studies
documented the beneficial neuroprotective effects of microglial
activation in removing β-amyloid plaques and decreasing the
inflammatory responses, thus controlling the progression of AD.
The decrease in the number of plaques might have been pro-
duced by phagocytosis of resident cells possibly stimulated via
a paracrine effect of the transplanted cells associated with the
plaques. In an elegant experiment, Simard et al. (2006) identified
two distinct origins of microglia in the AD brain and showed
that bone marrow-derived microglia were able to remove β-
amyloid from the extracellular environment whereas the resident
microglia had no effect on the presence of β-amyloid plaques.
Lee et al. (2009) showed that MSC transplantation stimulated
microglial activation in the brains of APP/PS1 mice that, in turn,
had neuroprotective effects, modulating inflammatory responses
and improving the cognitive decline associated with Aβ deposits.
In accordance with these studies, herein, we observed the forma-
tion of clusters of reactive microglia that co-localized with the
senile plaques. As 2xTg-AD animals aged, there was an increase
in the number of microglia that was stable in wild-type animals
as a function of age. The VEGF treatment was able to decrease
the number of microglia to the WT levels compared with the
untreated 2xTg-AD transgenic animals. The number of microglia
might have decreased in the VEGF-treated mice as a consequence
of the reduced number of β-amyloid plaques in the hippocampus.
CONCLUSION
Our findings suggest that the overproduction of VEGF by MSCs
(and possibly several other soluble factors secreted by MSCs)
favored neovascularization and the clearance of Aβ protein, which
ultimately recovered memory and learning deficits present in
these 2xTg-AD transgenic animals. In addition to explaining the
effects of MSCs in the pathophysiology of these AD transgenic
animals, this study has important therapeutic implications for the
vascular damage in the neurodegeneration promoted by AD.
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